Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to OCS. [ FAQ on what and how to ask] For non-OCS questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: Bahnhofstrasse 20, Zug, Switzerland, 6300
Employees: 60
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
CEO & Director
Chief Financial Officer
Chief Technology Officer
Chief Scientific Officer
Chief Legal Officer
Chief Human Resources Officer
Chief Business Officer
Chief Commercial Officer
President of Research & Development
Chief Development Officer
My Watchlist
